aclarubicin and Vomiting

Aclacinomycin-A (ACLA-A), the new anthracycline antibiotic that produces substantially less cardiotoxicity relative to doxorubicin, was evaluated in a phase II trial for advanced large cell and adenocarcinoma of the lung patients. Twenty-three patients with measurable disease were entered into the trial and received ACLA-A in doses of a weekly infusion of 65 mg/m2 and 85 mg/m2. Eighteen patients were evaluable for response and toxicity. Two patients were evaluable for toxicity only, one died before completion of a full course of therapy, and two did not receive the drug. There were no complete or partial remissions in this study. Three patients had disease stabilization for a median of 10 weeks (range 6-17). Toxicity was mainly hematologic. Nausea and vomiting were moderate. ACLA-A, in the dose schedules used, appears to have no activity in large cell and adenocarcinoma of the lung.

Topics: Aclarubicin; Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Infusions, Parenteral; Leukopenia; Lung Neoplasms; Male; Middle Aged; Naphthacenes; Nausea; Thrombocytopenia; Vomiting

Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Genital Neoplasms, Female; Humans; Hydrocortisone; Middle Aged; Naphthacenes; Nausea; Peplomycin; Vomiting

Single agent activity of aclacinomycin A or aclarubicin (ACR) for acute leukaemia in adults was as follows: complete remission was achieved in 8 of 21 (38%) with untreated patients and 7 of 41 (17%) with prior chemotherapy; thus the overall complete remission rate was 24%. The optimal dose schedule was 14 mg/m2/d daily i.v. administration, and a median total dose of 200 mg/m2 and 16 days were necessary for induction of complete remission. In combination, with behenoyl ara-C, ACR, 6-mercaptopurine and prednisolone, complete remission was achieved in 40 of 60 (67%) previously untreated patients, and 41 of 65 (63%) with prior chemotherapy; thus the overall rate was 65%. In a phase II study of ACR for solid tumours, response was achieved in carcinoma of oesophagus (1/3), stomach (12/84, 14%), gall bladder (1/4), pancreas (1/8), lung (4/30, 13%), breast (6/33, 18%), uterus (1/4), ovary (3/9, 33%), head and neck (1/5) and sarcoma (1/5). Side-effects of ACR most frequently observed were nausea and vomiting (around 30%) and a moderate grade marrow suppression was noted. An ECG change was observed in 7%, but there were no cases of chronic heart failure.

Topics: Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Naphthacenes; Nausea; Neoplasms; Vomiting

Topics: Aclarubicin; Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Drug Evaluation; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Naphthacenes; Vomiting